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We describe two cases of donor-derived methicillin-
resistant Staphylococcus aureus (MRSA) bacteremia
that developed after transplantation of organs from a
common donor who died from acute MRSA endocar-
ditis. Both recipients developed recurrent MRSA
infection despite appropriate antibiotic therapy, and
required prolonged hospitalization and hospital read-
mission. Comparison of S. aureus whole genome
sequence of DNA extracted from fixed donor tissue
and recipients’ isolates confirmed donor-derived trans-
mission. Current guidelines emphasize the risk posed
by donors with bacteremia from multidrug-resistant
organisms. This investigation suggests that, particu-
larly in the setting of donor endocarditis, even a
standard course of prophylactic antibiotics may not be
sufficient to prevent donor-derived infection.
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Centers for Disease Control and Prevention; CT,
computed tomography; DTAC, Disease Transmission
Advisory Committee; ED, Emergency Department;
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tis B virus; HCV, hepatitis C virus; IDU, nonmedical
injection drug use; MDRO, multidrug-resistant organ-
ism; MRSA, methicillin-resistant Staphylococcus aure-
us; OPTN, Organ Procurement and Transplantation
Network; PCR, polymerase chain reaction; PFGE,
pulsed-field gel electrophoresis; PHS, U.S. Public
Health Service; PVL, Panton-Valentine leukocidin;
SNP, single nucleotide polymorphism; WGS, whole
genomic sequencing
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Introduction
Unexpected donor-derived infection transmission is con-
firmed in less than 1% of solid organ transplants and may
lead to allograft failure or recipient death (1). When organ
donors are deemed to be at high risk for infection with viral
blood-borne pathogens, specific recipient informed con-
sent regarding the risk of viral infection transmission is
advised (2). However, available guidelines do not describe
risk-stratification related to transmission of bacterial
infections from donors with endocarditis. Although suc-
cessful use of organs from donors with subacute bacterial
endocarditis without evidence of distant septic emboli has
been reported (3,4), recent reports have described
increased recipient morbidity and mortality associated
with transmission of multidrug-resistant organisms
(MDROs) (5–7). Potential donor-derived disease transmis-
sion events are reported to the Organ Procurement and
Transplantation Network (OPTN) per policy and reviewed
by the ad hoc OPTN Disease Transmission Advisory
Committee (DTAC) which categorizes each as to the
likelihood of disease transmission. Through representation
on DTAC, Centers for Disease Control and Prevention
(CDC) leads investigations of select cases of public health
importance. We investigated two cases of posttransplant
methicillin-resistant Staphylococcus aureus (MRSA) bac-
teremia in solid organ recipientswhose commondonor died
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of MRSA-related endocarditis complications. These cases
highlight the need for careful monitoring and follow-up
among recipients of organs from donors with acute MDRO
endocarditis for increased risk for donor-derived infections.
Case Reports
Epidemiologic review
Medical records of the donor and all organ recipients were
reviewed to characterize clinical courses, diagnostic
evaluations, and laboratory and radiographic data. Organ
donor autopsy recordswere reviewed. The organ donor and
both symptomatic recipients were hospitalized at different
facilities.
Organ donor
In December 2012, a male with history of nonmedical
injection drug use (IDU) was evaluated at an Emergency
Department (ED) for 2 days of progressive confusion and
somnolence. He was minimally responsive and febrile
(105.98F). Broad-spectrum antimicrobial therapy was initi-
ated for presumed bacterial meningitis. Computed tomog-
raphy (CT) of the head revealed a large right parietal
intracranial hemorrhage. Peripheral blood cultures collected
during the ED evaluation revealed the presence of MRSA.
The antimicrobial susceptibility test results are shown in
Table 1. His neurologic condition worsened and he was
declared brain dead within 24 h.
Donor eligibility screening included review of premortem
laboratory and radiographic data. A standardized medical
and social history questionnaire was administered to next-
of-kin. Given the history of active IDU, the donor was
deemed to be at increased risk for window period viral
blood-borne pathogen infection; serology and nucleic acid
testing for HIV, hepatitis B virus and hepatitis C virus
were nonreactive. Broad-spectrum antibiotics, including
vancomycin, were continued and no bacterial growth
was noted on subsequent donor blood cultures. The last
donor blood cultures were collected 3 days prior to
organ recovery. Pretransplant chest CT scan was remark-
able for left upper lobe lung infiltrate and transthoracic
echocardiogram revealed a 1-cm mobile mitral valve
vegetation.
The lungs, kidneys, pancreas and liver were recovered
approximately 36 h after brain death and transplanted into
four recipients. By the time of organ recovery, the donor
had received antimicrobial therapy against MRSA infection,
consisting of 2 g of vancomycin in the ED and 1 g after
transfer to the tertiary referral center, and had remained
afebrile for >48h. Independent of organ donation, an
autopsy was performed and cause of death was attributed
to cerebral hemorrhage resulting from septic emboli.
Standard informed consent along with informed consent
for increased risk donors due to IDU was obtained from
recipients but did not specify donor MRSA endocarditis.
Lung recipient
The bilateral lung recipient had no previous history ofMRSA
infection or colonization, including a negative screening
nasal swab collected 7 days before transplantation for
hypersensitivity pneumonitis and interstitial lung disease
related to common variable immunodeficiency. A routine
intraoperative lung biopsy culture was positive for MRSA.
Vancomycin therapy was initiated at the time of transplan-
tation given donor MRSA bacteremia. However, surveil-
lance blood cultures collected 6 days after transplantation
revealedMRSA growth. Despite targeted antibiotic therapy
continued at therapeutic doses, MRSA growth was
observed on four surveillance bronchoalveolar lavage
(BAL) cultures collected during the subsequent 6 weeks
Table 1: Staphylococcus aureus antimicrobial susceptibility testing results with minimum inhibitory concentration (MIC) and susceptible/
intermediate/resistant (SIR) determination for cultures collected from a common organ donor and lung and liver recipients
Organ donor Lung recipient Liver recipient
Specimen type
Blood Lung biopsy Blood1 BAL BAL BAL BAL1 Blood Blood1
Day 3 Day 0 Day 6 Day 15 Day 20 Day 43 Day 159 Day 0 Day 72
Antibiotic MIC SIR MIC SIR MIC SIR MIC SIR MIC SIR MIC SIR MIC SIR MIC SIR MIC SIR
Clindamycin 0.5 S 0.25 S 0.25 S 0.25 S 0.25 S 0.25 S 0.25 S 0.25 S 0.25 S
Daptomycin 0.5 S 0.5 S 0.5 S 0.5 S
Gentamicin 0.5 S 0.5 S 2 S 0.5 S 0.5 S 0.5 S 0.5 S 2 S
Levofloxacin >4 R >4 R 8 R 8 R 8 R 8 R 8 R 8 R
Linezolid 2 S 2 S 2 S 2 S 2 S 2 S 2 S 2 S 2 S
Oxacillin >2 R >2 R >16 R 4 R 4 R 4 R 4 R >16 R
TMP/SMX 2/38 S 10 S 0.5/9.5 S 10 S 10 S 10 S 10 S 10 S 0.5/9.5 S
Vancomycin 2 S 2 S 0.5 S 1 S 1 S 1 S 1 S 1.5 S 2 S
BAL, bronchoalveolar lavage; Day 0, day of transplant; TMP/SMX, trimethoprim/sulfamethoxazole.
1Tested at the Centers for Disease Control and Prevention using broth microdilution.
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(Table 1). The patient did not develop signs or symptoms
consistent with MRSA infection during this time. After
completion of 9weeks of antibiotic therapy, a negative BAL
culture result was obtained 99 days after transplantation.
Nearly 6 months posttransplantation, the patient was
readmitted with complaints of increasing dyspnea on
exertion. Admission vital signs were within normal limits.
Chest radiography revealed large right-sided pleural effusion
and chest CT suggested extensive right-sided multifocal
consolidation. Diagnostic bronchoscopy was performed
and BAL culture revealed MRSA. Following 4 weeks of
vancomycin therapy, symptoms resolved. Throughout
the clinical course, vancomycin dosing was appropriate
(trough levels maintained between 15 and 20mg/mL)
and mean inhibitory concentration was 1mg/mL on all
isolates.
The blood isolate from day 6 and the BAL isolate from
day 159 posttransplant were submitted to CDC for
characterization by spa-typing, pulsed-field gel electropho-
resis (PFGE) and whole-genome sequence analysis.
Liver recipient
The liver recipient had a history of ulcerative colitis and
primary sclerosing cholangitis, and was receiving empiric
daptomycin at 4mg/kg for lower extremity cellulitis at the
time of transplantation. The intraoperative liver biopsy
culture was negative, but when MRSA growth was
observed on blood cultures collected from the recipient
3 h after transplantation, daptomycin therapy was contin-
ued at 6mg/kg dose for 14 days. Subsequent blood cultures
were negative. The patient was discharged to a long-term
care rehabilitation facility but was re-admitted 58 days later
with fever and chills. Blood cultures were positive for
MRSA and this isolate was submitted to CDC for
characterization. No evidence of hepatic abscess was
observed on CT scan. The patient was unable to tolerate
trans-esophageal echocardiogram, but trans-thoracic echo-
cardiogram did not identify valvular vegetation. A 6-week
course of vancomycin therapy was initiated with resolution
of symptoms and subsequent negative blood cultures.
Neither of the symptomatic recipients had chronic indwell-
ing devices, both received tacrolimus, mycophenolate
mofetil, and prednisone for immunosuppression, and
both remained asymptomatic at 1 year follow-up.
Kidneys and pancreas recipients
Screening peripheral blood cultures collected from the left
kidney and pancreas recipient and the right kidney recipient
revealed no growth. These recipients received transplants
for complications related to type 1 and type 2 diabetes
mellitus, respectively. Both patients received five doses of
vancomycin prophylaxis following transplantation and had
no signs or symptoms consistent with MRSA infection.
Laboratory Methods
Histopathological analysis
Archived formalin-fixed paraffin-embedded (FFPE) autopsy tissue speci-
mens of the mitral valve and central nervous system tissue of the donor
were evaluated using hematoxylin and eosin and Lillie-Twort Gram stain.
Tissue sections were also evaluated using an immunohistochemical assay
to detect specifically S. aureus with a hyperimmune mouse anti-S. aureus
ascitic fluid diluted at 1:100 (8).
Characterization of S. aureus
DNAwas extracted and amplified from single 16-mmsections of FFPEmitral
valve tissue as previously described (9), from the lung recipient’s blood and
BAL isolates, and from the liver recipient’s blood isolate (10,11). Real-time
polymerase chain reaction (PCR) was performed to detect the nuc gene, an
S. aureus-specific marker; mecA, which confers methicillin resistance; and
lukS-PV (Panton-Valentine) leukocidin (PVL) (10,12,13). Assignment of
SCCmec type and PFGE were performed as previously described (11).
The polymorphic X region of spa was amplified and sequenced as
described (14). The spa typing plug-in tool of BioNumerics v5.1 (Applied
Maths, Austin, TX) synchronizedwith the SeqNet/Ridom spa server (15)was
used to assign spa types. A pulsed-field type of USA300 was inferred for S.
aureus whose spa types correlated with multilocus sequence clonal
complex 8 and were PCR-positive for PVL and SCCmec IVa subtype.
Brothmicrodilution antimicrobial susceptibility was performed on all isolates
submitted to CDC (16).
Whole genomic sequencing (WGS) was performed using DNA extracted
from each transplant-associated isolate and FFPE mitral valve tissue of the
donor on the Illumina MiSeq Benchtop sequencer, as similarly de-
scribed (9,17). Reads were aligned against the reference USA300-0114
genome, FPR3757, using Novoalign (http://www.novocraft.com), and single
nucleotide polymorphisms (SNPs) were determined using GATK (http://
www.broadinstitute.org/gatk/). Reads containing insertions or deletions,
and thosemapping tomultiple locations in the referencewere removed from
the final alignments. SNPs were excluded if they did not meet a minimum
coverage of 10 and if the variant was present in less than 90% of the base
calls for that position. Finally, loci that were not present in all strains were
removed and a matrix containing the remaining orthologous SNPs was
generated. Phylogenetic trees of recipient and background isolate genomes
were constructed using maximum parsimony analysis in MEGA5 (http://
www.megasoftware.net). Background genomes included 10 previously-
sequenced epidemiologically unrelated isolates recovered between
years 2004 and 2012 from eight states with indistinguishable PFGE patterns
(Figure 1).
Laboratory Results
Histopathological analysis
Histological examination of the mitral valve of the donor
revealed a large fibrinous vegetation containing abundant
colonies of Gram-positive and coccoid bacteria. Small
clusters of Gram-positive cocci were also identified with
numerous septic emboli in the central nervous system of
the donor. An immunohistochemical assay specific for S.
aureus demonstrated intense staining specific in these
same tissues (Figure 2).
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Strain characterization
MRSA isolates from the lung and liver recipients were
indistinguishable by PFGE and were designated USA300-
0114 (not shown), the dominant community-associated
MRSA strain in the United States (11). Like these isolates,
S. aureus DNA extracted from the donor’s mitral valve
demonstrated spa type t008, mec type IVa, and was PVL-
positive. All isolates had identical antibiotic susceptibility
test results (Table 1). Phylogenetic analysis using WGS
showed the donor and recipient isolates were more closely
related to each other than the 10 background isolates. Only
one SNP was identified among the recipient isolate
genomes; 508 SNPs were identified among the recipient
and background S. aureus genomes analyzed here. These
data support previous conclusions that the USA300-0114
strain type is highly clonal (11), and provide empirical
evidence that the recipients’ isolates originated from the
same source.
Discussion
This report describes MRSA transmission through solid
organ transplantation from a deceased donor with acute
MRSA endocarditis and embolic stroke. These findings
underscore the challenges of transplant-transmittedMRSA
infection management among immunosuppressed solid
organ recipients. Furthermore, they emphasize the need to
balance the risks of using organs from donors with acute
MDRO endocarditis with the potential life-saving benefits
of organ transplantation. Organs from donors with acute
MDRO endocarditis should be accepted only after a careful
risk-benefit analysis of potential recipient adverse out-
comes, and clinicians should carefully monitor solid organ
recipients for delayed development of refractory, or
recurrent donor-derived infections. This report further
highlights the importance of linking novel laboratory
methods with epidemiologic investigation when investigat-
ing donor-derived bacterial infections.
The risk of fatal neurologic complications from MRSA
endocarditis among injection drugs users has been
described (18). U.S. Public Health Service guidelines define
medical and behavioral characteristics among organ
donors associated with increased risk of blood-borne viral
infections (2), but currently there are no guidelines for
infection risks associated with using organs from donors
with acute MDRO bacterial endocarditis. While organ
transplantation may be the optimal treatment for many
patients with end-stage organ disease, MDRO infection in
the transplant setting is associatedwith increasedmortality
risk for the recipient due to immunosuppression and limited
therapeutic options (7). An increasing number of potential
organ donors are admitted to intensive care units where
they are exposed to MDROs, and organ recovery and
transplantation may occur prior to knowledge of final
MDRO culture results (19). Given the growing number of
patients awaiting transplantation, shortage of available
organs, and increasing numbers of donors with potential
multidrug-resistant infections, donor-derived transmission
of MDRO bacterial infections may increase in the
future (20,21). Expansion of guidelines to include potential
risks of adverse recipient outcomes associated with using
organs from donors with acute MDRO endocarditis should
be considered.
In this investigation, two organ recipients developed
recurrent or persistent MRSA infection following trans-
plant. Occult septic embolization, particularly from mitral
valve vegetation, in the setting of MRSA bacteremia and
endocarditis has been described (22,23). The median time
to clearance ofMRSAbacteremia is typically between 7 and
9 days (24). In the liver recipient, the MRSA-positive blood
cultures collected 3 h after transplantation may reflect
persistence of the donor MRSA bloodstream infection,
despite antibiotic therapy, at the time of liver procurement.
The recurrence of bacteremia in the liver recipient after
2 weeks of vancomycin therapy may reflect incomplete
treatment. High-grade donor bacteremia likely resulted in
extensive infection in transplanted organs. While clinical
guidelines for MRSA bacteremia recommend 2 weeks of
antimicrobial therapy for uncomplicated infections, extend-
ing therapy to 4 weeks may provide further benefit in
resolving infection in immunosuppressed solid organ
recipients (24,25). While radiographic evidence did not
suggest abscesses in either recipient, it is also possible that
the persistence of MRSA in the lung recipient’s BAL
 Donor: FFPE heart valve tissue
 Lung recipient: BAL* isolate
 Lung recipient: blood isolate
 Liver recipient: blood isolate
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Figure 1: A single maximum parsimony tree was
reconstructed using 508 SNPs from 15 whole genome
USA300-0114 sequences of 3 MRSA recipient isolates, 1
donor isolate, 1 reference (FPR3757) and 10 background
USA300-0114 isolates.Background genomes are labeledwith the
state and year collected. Donor and recipient isolates are labeled as
such with the clinical source indicated. Branch lengths represent
the genetic distance with the numbers on each branch indicating
the number of SNPs between genomes. The bar represents 10
SNPs. Tree constructed using MEGA5. BAL, bronchoalveolar
lavage. MRSA, methicillin-resistant Staphylococcus aureus; SNPs,
single nucleotide polymorphisms.
Wendt et al
2636 American Journal of Transplantation 2014; 14: 2633–2639
cultures and recurrence of MRSA bacteremia in both the
liver and lung recipients may have resulted from occult,
undetected micro-abscesses which did not resolve despite
prolonged antibiotic therapy.
This report also highlights the importance of linking novel
laboratory methods with epidemiologic investigation when
investigating donor-derived bacterial infections. Donor
cultures are frequently performed at reference laboratories
Figure 2: (A) Gross appearance of a perforating bacterial vegetation on the posterior leaflet of the mitral valve in the heart of the donor. (B)
Gross appearance of a cystic lesion in the white matter of the right cerebral hemisphere of the donor formed by a large intracerebral
hematoma. (C) Histological appearance of the mitral valve vegetation showing fibrin (pink) admixed with innumerable clumps of bacteria
(blue). Hematoxylin and eosin stain, originalmagnification12.5. (D) Tissue Gram stain ofmitral valve lesion showing coalescing colonies of
Gram-positive, coccoid bacteria. Lillie-Twort stain, original magnification100. (E) Occlusive septic embolus in a small vessel in the cerebral
cortex, revealing numerous coccoid bacteria enmeshed in fibrin. Hematoxylin and eosin stain, original magnification158. (F) Same vessel
as image (E), demonstrating immunohistochemical evidence of infection with Staphylococcus aureus (red). Immunoalkaline phosphatase
technique with naphthol-fast red and hematoxylin counterstain, original magnification 158.
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distant to the donor organ procurement organization
and communication of findings is often slower than for
hospital-based laboratories, particularly when highly resis-
tant organisms are cultured. While donor sera must be
archived for 10 years following organ procurement, there
are no public health recommendations or policy standards
for archiving donor bacterial culture isolates. As a result,
these specimensmay not be available for laboratory testing
when donor-derived transmission events are suspected.
In the present investigation, the novel application of
molecular characterization of DNA extracted from FFPE
tissue, combined with characterization of isolates, permit-
ted comparison ofMRSA from donor and recipient sources,
all of which were characterized as USA300, the most
common cause of community-acquired MRSA infection in
the United States (11). The predominance of this clone
among community-acquired MRSA infections left open the
possibility that the organ recipients had acquired this strain
as a cause of remote infection from a community source
rather than an indolent transplant-associated infection.WGS
analysis was employed to investigate relatedness of strains
infecting the donor and recipient, and strongly supported
organ donation as the common source of infection in the
lung and liver recipients by clearly showing that the donor
and recipient isolates were more closely related to each
other than they were to the background isolates. Further-
more, only one SNP among the transplant group indicates
that these strains are from a common source. Estimates of
the mutation rate for S. aureus have been calculated
repeatedly at one SNP every 6–7 weeks (26). In instances
where FFPE tissues are available, novel laboratory tools can
be used to confirm transplant transmissionwhen suspected
in association with donors at increased risk.
The increased risk of morbidity and mortality associated
with virulent MDROs underscores the importance of
recipient informed consent and vigilant posttransplant
clinical surveillance for timely and pathogen-appropriate
treatment in the event of donor-derived infection. Solid
organ donors with acute MDRO endocarditis with risks
of septic embolization may pose an additional morbidity
and mortality risk for organ recipients, and solid organ
transplantation should proceed only after an extensive risk-
benefit evaluation. Recognition and reporting of donor-
derived bacterial transmissions events is crucial to improv-
ing recipient outcome and tracking the magnitude of the
public health burden. Communication is crucial concerning
donor infection such as antimicrobial susceptibility, viru-
lence of the pathogen, and location in sites refractory to
treatment in gauging the risk of transmitted disease in the
recipient.
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